<?xml version="1.0" encoding="UTF-8"?>
<document id="28698647">
	<sentence id="s1" text="Prostate cancer is the most common cancer among western men, with a significant mortality and morbidity reported for advanced metastatic disease.">
		<entity id="s1.e1" charOffset="9-15"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<entity id="s1.e2" charOffset="56-59"
			type="GENE" text="men" ontology_id="8178"/>
		<pair id="s1.p1" e1="s1.e1"
		    e2="s1.e2" pgr="false"/>
	</sentence>
	<sentence id="s2" text="By analysing prostate cancer bone metastases using high density microarrays, we found a common genomic copy number loss at 6q16.1-16.2, containing the FBXL4 gene, which was confirmed in larger series of bone metastases by fluorescence in situ hybridisation (FISH).">
		<entity id="s2.e1" charOffset="22-28"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<entity id="s2.e2" charOffset="151-156"
			type="GENE" text="FBXL4" ontology_id="26235"/>
		<entity id="s2.e3" charOffset="258-262"
			type="GENE" text="FISH" ontology_id="9644"/>
		<pair id="s2.p1" e1="s2.e1"
		    e2="s2.e2" pgr="false"/>
		<pair id="s2.p2" e1="s2.e1"
		    e2="s2.e3" pgr="false"/>
	</sentence>
	<sentence id="s3" text="Loss of FBXL4 was also detected in primary tumours and it was highly associated with prognostic factors including high Gleason score, clinical stage, prostate-specific antigen (PSA) and extent of disease, as well as poor patient survival, suggesting that FBXL4 loss contributes to prostate cancer progression.">
		<entity id="s3.e1" charOffset="8-13"
			type="GENE" text="FBXL4" ontology_id="26235"/>
		<entity id="s3.e2" charOffset="43-50"
			type="HP" text="tumours" ontology_id="HP_0002664"/>
		<entity id="s3.e3" charOffset="177-180"
			type="GENE" text="PSA" ontology_id="3818"/>
		<entity id="s3.e4" charOffset="290-296"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s3.p1" e1="s3.e1"
		    e2="s3.e4" pgr="false"/>
		<pair id="s3.p2" e1="s3.e3"
		    e2="s3.e4" pgr="false"/>
		<pair id="s3.p3" e1="s3.e1"
		    e2="s3.e2" pgr="false"/>
		<pair id="s3.p4" e1="s3.e6"
		    e2="s3.e3" pgr="false"/>
	</sentence>
	<sentence id="s4" text="We also demonstrated that FBXL4 deletion is detectable in circulating tumour cells (CTCs), making it a potential prognostic biomarker by 'liquid biopsy'.">
		<entity id="s4.e1" charOffset="26-31"
			type="GENE" text="FBXL4" ontology_id="26235"/>
		<entity id="s4.e2" charOffset="70-76"
			type="HP" text="tumour" ontology_id="HP_0002664"/>
		<pair id="s4.p1" e1="s4.e1"
		    e2="s4.e2" pgr="false"/>
	</sentence>
	<sentence id="s5" text="In vitro analysis showed that FBXL4 plays a role in regulating the migration and invasion of prostate cancer cells.">
		<entity id="s5.e1" charOffset="30-35"
			type="GENE" text="FBXL4" ontology_id="26235"/>
		<entity id="s5.e2" charOffset="102-108"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s5.p1" e1="s5.e1"
		    e2="s5.e2" pgr="false"/>
	</sentence>
	<sentence id="s6" text="FBXL4 potentially controls cancer metastasis through regulation of ERLEC1 levels.">
		<entity id="s6.e1" charOffset="0-5"
			type="GENE" text="FBXL4" ontology_id="26235"/>
		<entity id="s6.e2" charOffset="27-33"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<entity id="s6.e3" charOffset="67-73"
			type="GENE" text="ERLEC1" ontology_id="27248"/>
		<pair id="s6.p1" e1="s6.e1"
		    e2="s6.e2" pgr="false"/>
		<pair id="s6.p2" e1="s6.e2"
		    e2="s6.e3" pgr="false"/>
	</sentence>
	<sentence id="s7" text="Therefore, FBXL4 could be a potential novel prostate cancer suppressor gene, which may prevent cancer progression and metastasis through controlling cell invasion">
		<entity id="s7.e1" charOffset="11-16"
			type="GENE" text="FBXL4" ontology_id="26235"/>
		<entity id="s7.e2" charOffset="53-59"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s7.p1" e1="s7.e1"
		    e2="s7.e2" pgr="false"/>
	</sentence>
</document>
